

## Effective Visual Communication (EVC) exercise: Case study

### Efficacy of Capmatinib in Non Small Cell Lung Cancer (NSCLC) with MET mutations

#### Background:

- Phase 2 study of Capmatinib (MET receptor inhibitor) in NSCLC patients with various MET mutations
- Primary endpoint: overall response (complete or partial response)
- Secondary endpoint: duration of response

#### Key question:

- Does Capmatinib show meaningful response in patients with various types of MET mutation?

**Reference** for additional background, purpose and key messages:

- Wolf et al. NEJM 2020, 383:944-957, <https://www.nejm.org/doi/full/10.1056/NEJMoa2002787>

#### Task 1:

- Complete the Purpose Worksheet (separate handout). It is already half filled.

#### Task 2:

- See the main visualization of the study results. Improve it or create your own to display the key message(s).

